Immunizing children to protect against the increasing risk of hepatitis A in adolescents and young adults in South Korea.
We evaluated the CR326F strain (VAQTA) derived hepatitis A vaccine in Korean children and adolescents >2 years of age to consider a future immunization program. In our study, the pediatric two-dose regimen of VAQTA was found to be generally well tolerated and resulted in 100% (95% CI 94.8, 100.0) seroconversion after 2 doses. Immunizing children with the HAV vaccine routinely should be considered in South Korea, particularly in areas where recent outbreaks have occurred.
Sohn
Y M
YM
Department of Pediatrics, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. ymsohn@navekids.co.kr
Lee
J S
JS
Park
J H
JH
Poerschke
G
G
Eves
K
K
Gress
J
J
Kuter
B
B
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks / Q000517:prevention & control*; D004334:Drug Administration Schedule; D005260:Female; D006506:Hepatitis A / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D017589:Immunization Programs; D007723:Korea; D008297:Male
D022362:Hepatitis A Vaccines